共 50 条
- [31] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41Lebwohl, MarkGooderham, MelindaWarren, Richard B.
- [32] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156Armstrong, April W.Warren, Richard B.Sofen, HowardSpelman, LyndaLeonardi, CraigBanerjee, SubhashisWang, TaoThroup, JohnColston, ElizabethNapoli, AndrewKimball, Alexa B.
- [33] Cumulative clinical benefit of treatment initiation with deucravacitinib vs. apremilast over 52 weeks for patients with moderate to severe plaque psoriasis in the POETYK PSO-1 trialAUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 21 - 21Gebauer, KurtArmstrong, April W.Park, Sang HeeChirikov, ViktorNicolas, PierreWang, Wei-JhihColombo, Matthew J.Patel, Vardhaman
- [34] Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and ApremilastARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4462 - 4465Merola, JosephMease, Philip J.Armstrong, April W.Strand, VibekeLehman, ThomasChoi, JiyoonBecker, BrandonZhong, YichenColombo, Matthew J.Thaci, DiamantBili, AndronikiGottlieb, Alice B.
- [35] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 29 - 39Armstrong, April W.Gooderham, MelindaWarren, Richard B.Papp, Kim A.Strober, BruceThaci, DiamantMorita, AkimichiSzepietowski, Jacek C.Imafuku, ShinichiColston, ElizabethThroup, JohnKundu, SudeepSchoenfeld, SteveLinaberry, MistiBanerjee, SubhashisBlauvelt, Andrew
- [36] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trialsBRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I61Kearney, NiamhPink, AndrewHoyt, KimKisa, Renata M.Banerjee, SubhashisRogers, AlexandraMullan, JillWarren, Richard B.
- [37] Deucravacitinib (DEUC), an Oral, Selective Tyrosine Kinase 2 ( TYK2) Inhibitor, Versus Placebo (PBO) and Apremilast (APR) in Moderate to Severe Plaque Psoriasis: Safety Analysis by Prior Therapy Subgroups in the Phase 3 POETYK PSO-1 and PSO-2 TrialsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 120Eyerich, KilianWarren, Richard B.Blauvelt, AndrewGudjonsson, JohannSobell, JeffreyBanerjee, SubhashisBalagula, EugeneHippeli, LaurenGooderham, Melinda
- [38] Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41Sobell, Jeffrey M.Eyerich, KilianBlauvelt, Andrew
- [39] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trialsAUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 29Foley, PeterZhang, JianzhongImafuku, ShinichiDing, YangfengOkubo, YukariLi, HuiTada, YayoiLi, LinfengOhtsuki, MamitaroPan, WeiliLu, YanHao, ChengXian, JiangHo, Ji-ChenGuo, ShupingSeo, Seong JunNapoli, AndrewChatterjee, ArkenduKisa, Renata M.Banerjee, SubhashisMorita, Akimichi